Harvard Bioscience appoints Stephen DeNelsky to board of directors

Harvard Bioscience Inc. (NASDAQ: HBIO) announced the appointment of Stephen DeNelsky to its board of directors, effective September 5, 2025. DeNelsky will also serve on the board's Nominating and Governance Committee.

DeNelsky brings 30 years of experience in research, analysis, and valuation of public and private equities in the healthcare industry. He currently serves as managing director at Oaktree Capital Management and has held senior roles at Marathon Asset Management and Life Sciences Alternative Funding.

"His knowledge across the verticals we operate in, as well as his expertise in guiding life sciences companies on financial strategy will be invaluable as we move forward," said John Duke, president and CEO of Harvard Bioscience.

DeNelsky has worked across major healthcare sub-sectors, including life sciences, pharmaceuticals, devices and services. He currently serves on the board of Visioncare Inc. and previously served on the boards of Integrated Diagnostics and AMICAS Inc.

DeNelsky received a bachelor's degree in economics from American University and an MBA from the University of Maryland.

"I'm honored to join the Board and look forward to contributing to thoughtful governance and long-term value creation at Harvard Bioscience," DeNelsky said.

Harvard Bioscience develops, manufactures and sells technologies, products and services for life science applications, including research, drug and therapy discovery, bio-production and preclinical testing. The company operates in the United States, Europe, and China.

You May Also Be Interested In

• Gyre Therapeutics adds three directors to its board
• Cheche Group to execute 35-for-1 share consolidation on Nasdaq
• EMA backs orphan drug status for Vanda's imsidolimab in rare skin disease